Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The 5 Million Dollar Priviate Placement was oversubscribed to
7 Million. The company is doing a PP at this time for 3 million with a 50% over allotment to 4.5 Million if it is oversubscribed.
Blackcat7717
To All Investors: Do you Due Diligence. Start at IMUN.COM
Check the numerous Press Releases. After you do all
of this and you decide this stock is a pump and dump,just move on.
Then you could buy APPLE at 600.00 and hold for your kids.
Also their is a 3 FORM 4 filed by the CEO Seth Shaw he bought an adittional 75,000@ $.2638.
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
1. Name and Address of Reporting Person *
SHAW SETH M 2. Issuer Name and Ticker or Trading Symbol
Immunovative, Inc. [ IMUN ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__ X __ Director _____ 10% Owner
__ X __ Officer (give title below) _____ Other (specify below)
Chief Executive Officer
(Last) (First) (Middle)
C/O IMMUNOVATIVE, INC., 39 OLD RIDGEBERRY ROAD 3. Date of Earliest Transaction (MM/DD/YYYY)
10/11/2012
(Street)
DANBURY, CT 06180
(City) (State) (Zip) 4. If Amendment, Date Original Filed (MM/DD/YYYY)
6. Individual or Joint/Group Filing (Check Applicable Line)
_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.00001 10/11/2012 P 75000 A $.2638 1350000 D
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 8. Price of Derivative Security
(Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
SHAW SETH M
C/O IMMUNOVATIVE, INC.
39 OLD RIDGEBERRY ROAD
DANBURY, CT 06180 X
Chief Executive Officer
Signatures
/s/ Seth Shaw 10/11/2012
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Blackcat7717
Profitable day today closed at $.27 cents up .03
Blackcat7717
FORM 4 Purchase by CEO. There are 2 purchases. 1ST 100,000 @ $.24 2ND purchase 175,000 @ $20.5
FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
1. Name and Address of Reporting Person *
SHAW SETH M 2. Issuer Name and Ticker or Trading Symbol
Immunovative, Inc. [ IMUN ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__ X __ Director _____ 10% Owner
__ X __ Officer (give title below) _____ Other (specify below)
Chief Executive Officer
(Last) (First) (Middle)
C/O IMMUNOVATIVE, INC., 39 OLD RIDGEBERRY ROAD 3. Date of Earliest Transaction (MM/DD/YYYY)
10/5/2012
(Street)
DANBURY, CT 06180
(City) (State) (Zip) 4. If Amendment, Date Original Filed (MM/DD/YYYY)
6. Individual or Joint/Group Filing (Check Applicable Line)
_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.00001 10/5/2012 P 175000 A $.2037 1175000 D
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 8. Price of Derivative Security
(Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
SHAW SETH M
C/O IMMUNOVATIVE, INC.
39 OLD RIDGEBERRY ROAD
DANBURY, CT 06180 X
Chief Executive Officer
Signatures
/s/ Seth Shaw 10/5/2012
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
NEWS OUT! ImmunovativeINC
Press Release
IMMUNOVATIVE, INC. ANNOUNCES ISSUANCE OF U.S. PATENT ON KEY SCIENTIFIC BREAKTHROUGH
NEW YORK, NY--(Marketwire -10/11/2012)- Immunovative, Inc. ("IMUN" or the “Company”) (OTCBB: IMUN) has today announced that Immunovative Therapies, Ltd. (“ITL”) has been granted a U.S. Patent entitled "METHOD FOR ALLOGENEIC CELL THERAPY," which was issued September 25, 2012, under Patent No. 8,273,377. Foreign versions of this patent are pending around the world. This patent covers the proprietary method that utilizes immune cells from a normal donor to elicit an anti-tumor mechanism that mimics the Graft vs Tumor (GVT) effect of non-myeloablative allogeneic stem cell transplants (“Mini-Transplant’) without the toxicity of Graft vs. Host Disease (GVHD). Harnessing the power of the immune system to treat cancer and infectious disease has long been the goal of physicians and scientists. Unfortunately, cancer vaccines and cell immunotherapy methods have had difficulties in translating the promise of immune control into effect treatments. The most effective anti-cancer mechanism ever discovered is the GVT immune response that occurs after Mini-Transplant procedures. This mechanism can completely destroy chemotherapy-resistant metastatic cancers. Unfortunately, the clinical use of the GVT effect is severely limited due to extreme toxicity of an intimately related GVHD effect. Mini-Transplants are thus only widely used in advanced cases of leukemia, even though the GVT effect has been shown capable of killing many types of solid tumors. The separation of the beneficial GVT effect from the devastating GVHD toxicity has long been the goal of stem cell transplant scientists and is the subject of extensive research around the world.
ITL is believed to be the first to develop an immunotherapy drug product (AlloStimTM) which enables the harnessing of the power of the GVT mechanism without GVHD side effects. ITL calls the mechanism which enables immune-mediated tumor destruction without GVHD toxicity the “Mirror EffectTM”. The “Mirror EffectTM” mechanism represents a major breakthrough for treatment of cancer and infectious disease. Early human clinical trials have produced evidence of this technology’s capability to stimulate the immune systems of heavily pre-treated metastatic cancer patients to kill widely disseminated metastatic cancers. Potentially pivotal, double-blind, placebo-controlled Phase II/III clinical trial in metastatic breast cancer is being prepared to document these effects in a controlled setting and determine if the immune-mediated tumor debulking provides patients with a survival advantage. This issued US Patent covers the use of intentionally mismatched, activated immune cells for treatment of cancer and infectious diseases. The patent discloses the concepts and methods related to ITL’s proprietary “Mirror EffectTM” technology and describes it’s lead immunotherapy drug candidate “AlloStimTM”. This patent also describes how AlloStimTM eliminates the need for a matched tissue donor and chemotherapy pre-conditioning for patients that require a bone marrow or stem cell transplant .
The newly issued patent is part of an intellectual property portfolio from ITL that includes 11 issued patents and numerous patent applications, to which IMUN has exclusive rights in the US and rest of the world. The licensed patents cover compositions, methods of production, formulation, distribution and uses for treatment of all types of cancer and infectious diseases.
Seth M. Shaw, CEO of IMUN stated: “The separation of the beneficial GVT effect from the devastating GVHD toxicity has been called the ‘Holy Grail” of transplant research. ITL is the first to accomplish this significant scientific milestone. We are confident that ITL’s extensive Intellectual Property ("IP") portfolio will provide our products with long-term market exclusivity. This patent is an important component of our growing IP estate, as the allowed claim language is very broad. We are now the exclusive allogeneic cell therapy company in the world. Our strong patent portfolio will now allow us to pursue opportunities for partnering and sub-licensing by indication and territory around the world.”
Dr. Michael Har-Noy, CEO, founder of ITL and inventor of the “Mirror EffectTM technology stated: “Our patent portfolio is a valuable asset as it not only protects our AlloStimTM and AlloVaxTM product candidates, but also provides protection of the unique mechanism of action that enables these products to have such powerful potential to debulk treatment-resistant metastatic disease. We are continuing to invest in research activities to improve our current product candidates and develop new products and further expand our patent portfolio. With protection of the novel mechanism of action, ITL and IMUN have the basis for development of a new industry based on powerful, non-toxic immunotherapy products that can work where all current treatment options have failed. ”
About Immunovative, Inc.:
On December 12th, 2011, Immunovative, Inc. ("IMUN") signed an exclusive License Agreement (the "License Agreement") with Immunovative Therapies, Ltd. ("ITL"). Under the terms of the License Agreement, IMUN has been granted an exclusive, worldwide license to commercialize any products covered under ITL's current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products. Please visit IMUN’s website at www.imun.com.
About Immunovative Therapies, Ltd.:
Immunovative Therapies, Ltd. is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israeli Office of the Chief Scientist. ITL is a graduate of the Misgav Venture Accelerator, a member of the world-renowned Israeli technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. ITL specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for treatment of cancer and infectious disease. Please visit ITL’s website at: www.immunovative.co.il
DISCLAIMER:
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on IMUN's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which IMUN has little or no control. Such forward-looking statements are made only as of the date of this release, and IMUN assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by IMUN with the Securities and Exchange Commission.
For more information please contact:
Mr. Seth Shaw
Chairman & Chief Executive Officer
Immunovative, Inc.
New York: +1-917-796-9926
Montreal: +1-514-840-3697
Email: sshaw@imun.com
NEWS OUT! ImmunovativeINC
Press Release
IMMUNOVATIVE, INC. ANNOUNCES ISSUANCE OF U.S. PATENT ON KEY SCIENTIFIC BREAKTHROUGH
NEW YORK, NY--(Marketwire -10/11/2012)- Immunovative, Inc. ("IMUN" or the “Company”) (OTCBB: IMUN) has today announced that Immunovative Therapies, Ltd. (“ITL”) has been granted a U.S. Patent entitled "METHOD FOR ALLOGENEIC CELL THERAPY," which was issued September 25, 2012, under Patent No. 8,273,377. Foreign versions of this patent are pending around the world. This patent covers the proprietary method that utilizes immune cells from a normal donor to elicit an anti-tumor mechanism that mimics the Graft vs Tumor (GVT) effect of non-myeloablative allogeneic stem cell transplants (“Mini-Transplant’) without the toxicity of Graft vs. Host Disease (GVHD). Harnessing the power of the immune system to treat cancer and infectious disease has long been the goal of physicians and scientists. Unfortunately, cancer vaccines and cell immunotherapy methods have had difficulties in translating the promise of immune control into effect treatments. The most effective anti-cancer mechanism ever discovered is the GVT immune response that occurs after Mini-Transplant procedures. This mechanism can completely destroy chemotherapy-resistant metastatic cancers. Unfortunately, the clinical use of the GVT effect is severely limited due to extreme toxicity of an intimately related GVHD effect. Mini-Transplants are thus only widely used in advanced cases of leukemia, even though the GVT effect has been shown capable of killing many types of solid tumors. The separation of the beneficial GVT effect from the devastating GVHD toxicity has long been the goal of stem cell transplant scientists and is the subject of extensive research around the world.
ITL is believed to be the first to develop an immunotherapy drug product (AlloStimTM) which enables the harnessing of the power of the GVT mechanism without GVHD side effects. ITL calls the mechanism which enables immune-mediated tumor destruction without GVHD toxicity the “Mirror EffectTM”. The “Mirror EffectTM” mechanism represents a major breakthrough for treatment of cancer and infectious disease. Early human clinical trials have produced evidence of this technology’s capability to stimulate the immune systems of heavily pre-treated metastatic cancer patients to kill widely disseminated metastatic cancers. Potentially pivotal, double-blind, placebo-controlled Phase II/III clinical trial in metastatic breast cancer is being prepared to document these effects in a controlled setting and determine if the immune-mediated tumor debulking provides patients with a survival advantage. This issued US Patent covers the use of intentionally mismatched, activated immune cells for treatment of cancer and infectious diseases. The patent discloses the concepts and methods related to ITL’s proprietary “Mirror EffectTM” technology and describes it’s lead immunotherapy drug candidate “AlloStimTM”. This patent also describes how AlloStimTM eliminates the need for a matched tissue donor and chemotherapy pre-conditioning for patients that require a bone marrow or stem cell transplant .
The newly issued patent is part of an intellectual property portfolio from ITL that includes 11 issued patents and numerous patent applications, to which IMUN has exclusive rights in the US and rest of the world. The licensed patents cover compositions, methods of production, formulation, distribution and uses for treatment of all types of cancer and infectious diseases.
Seth M. Shaw, CEO of IMUN stated: “The separation of the beneficial GVT effect from the devastating GVHD toxicity has been called the ‘Holy Grail” of transplant research. ITL is the first to accomplish this significant scientific milestone. We are confident that ITL’s extensive Intellectual Property ("IP") portfolio will provide our products with long-term market exclusivity. This patent is an important component of our growing IP estate, as the allowed claim language is very broad. We are now the exclusive allogeneic cell therapy company in the world. Our strong patent portfolio will now allow us to pursue opportunities for partnering and sub-licensing by indication and territory around the world.”
Dr. Michael Har-Noy, CEO, founder of ITL and inventor of the “Mirror EffectTM technology stated: “Our patent portfolio is a valuable asset as it not only protects our AlloStimTM and AlloVaxTM product candidates, but also provides protection of the unique mechanism of action that enables these products to have such powerful potential to debulk treatment-resistant metastatic disease. We are continuing to invest in research activities to improve our current product candidates and develop new products and further expand our patent portfolio. With protection of the novel mechanism of action, ITL and IMUN have the basis for development of a new industry based on powerful, non-toxic immunotherapy products that can work where all current treatment options have failed. ”
About Immunovative, Inc.:
On December 12th, 2011, Immunovative, Inc. ("IMUN") signed an exclusive License Agreement (the "License Agreement") with Immunovative Therapies, Ltd. ("ITL"). Under the terms of the License Agreement, IMUN has been granted an exclusive, worldwide license to commercialize any products covered under ITL's current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products. Please visit IMUN’s website at www.imun.com.
About Immunovative Therapies, Ltd.:
Immunovative Therapies, Ltd. is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israeli Office of the Chief Scientist. ITL is a graduate of the Misgav Venture Accelerator, a member of the world-renowned Israeli technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. ITL specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for treatment of cancer and infectious disease. Please visit ITL’s website at: www.immunovative.co.il
DISCLAIMER:
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on IMUN's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which IMUN has little or no control. Such forward-looking statements are made only as of the date of this release, and IMUN assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by IMUN with the Securities and Exchange Commission.
For more information please contact:
Mr. Seth Shaw
Chairman & Chief Executive Officer
Immunovative, Inc.
New York: +1-917-796-9926
Montreal: +1-514-840-3697
Email: sshaw@imun.com
Form -4 Insider buying.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8503829
KLC
Form 3 File with the SEC. by the CEO.
http://www.istockanalyst.com/article/viewsecfiling/articleid/6077914
Blackcat7717
News Out! Northwestern University Feinberg School of Medicine.
Blackcat7717
Ocean I am very glad you are on our team. Your post was
on the MONEY. When the FDA hold is lifted between now and
the end of the year hopefully. The share price should move
to $1.00 at least. An investor downside is about .05 cents 25%
and the upside at $1.00 is 500 %. Sounds like good odds to me.
Blackcat7717
Stockgrinder, We cannot be upset if the SHORT seller have
some press. However that came out in July. They are not having
to much luck. IMUN has put out about 10 positive press releases since July.
Blackcat7717
Badman I cannot wait for Scores to go to $.25 -$.50. Did you ever buy NVNC
I Posted #529 at .12. The company changed it symbol from NVNC to IMUN. Check it out!
www.IMUN.com
Blackcat7717
Investors check out this article: I hope IMUN can get some of
this 3 Billion dollars on a grant.
http://cmf.chron.com/news/health/article/M-D-Anderson-launches-3-billion-fight-against-3882246.php
Blackcat7717
I sure you can. It is determined by the Brokage Firm
you do business with.
Blackcat7717
Thank You Badman for your update. I found a profile on Robert M. Gans. Most of the info we know, but it is good to have for new
investors.
Executive Profile*
Robert M. Gans
Chief Executive Officer, President and Director, Scores Holding Co. Inc.
Age Total Calculated Compensation This person is connected to 3 board members in 1 different organizations across 2 different industries.
See Board Relationships
63 --
As of Fiscal Year 2010
Background*
Mr. Robert M. Gans has been the Chief Executive Officer and the President of Scores Holding Co. Inc. since August 6, 2010. Mr. Gans has been an Executive Vice President, General Counsel and Secretary of Pricesmart Inc. since August 1997. He is the owner of Mitchell's East LLC. He served as an Executive Vice President and General Counsel of Pricesmart Enterprises Inc. from October 1994 to July 1997. He served as the senior member of the law firm of Gans, Blackmar & Stevens, ... A.P.C., of San Diego, California from 1988 to October 1994. He has been a Director of Scores Holding Co. Inc. since August 6, 2010. Mr. Gans graduated from University of California-Los Angeles School of Law in 1975.
Read Full Background
Corporate Headquarters*
533-535 West
New York, New York 10001
United States
Phone: 212-868-4900
Fax: --
Board Members Memberships*
2010-Present
Chief Executive Officer, President and Director
Scores Holding Co. Inc.
Blackcat7717
This is the way I understand the future merger. The company IMUN has 2 years from the date they signed with ITL to pay them $10 Million dollars. The 10 Million Dollars will be paid after the results of the Phase II- III trials in Europe. If the results of the new trials are equal to the Phase I or better the 10 Million will go to ITL from IMUN and the merger will be completed. Also the hold from the FDA must be lifted before the merger. ITL will own 75% of the merged company and IMUN will own 25% at a pre determined value at that time. Whatever the stock price is at that
time both ITL shares & IMUN shares will be at the same value.
Blackcat7717
I have a potential update in reference to possible short selling.
The company is currently doing a Private Placement @ $.175 cents.
It is possible that some current shareholders are selling stock
they bought 1 year ago and buying restricted stock back from the company. They will have to hold the NEW shares for 6 months or more to remove the restriction. If this is so it ends up being a good thing for the company. The company will try to raise between $3.5 Million dollars to a MAX. of $5.25 Million. The Min.stock purchase is $50,000 dollars U.S. That means the stock will trade between $.20- .25 until the Private Placement is done. (approx. 20% discount to the current market price.)The company recently raised almost $7 Million dollars at $.10. When this Private Placement is complete I look forward to a price movement in the stock. Additional good news also is I do not think the stock price will go below $.175 cents. I now think we DO NOT have a short selling problem.
Blackcat7717
Someone is bidding @ .20 for 428,000 shares on level 2 quote!
Blackcat7717
Whitedog3 I am sorry to hear about your sister. Your sister had to be an unselfish person to donate her organs to save others. Make no mistake, if this stock is being shorted at this level the shorts have to cover at a lower price or a higher price. My bet is they will cover at a higher price. Dr Har-Noy is doing his best to notify the investing public about these amazing stories like your sister and the man you met at the clinic. We are at the early stage of a facinating journey to help many cancer patients. I am Long And Strong. I am a true believer also.
Blackcat7717
NEWS:http://www.sys-con.com/node/2345799
Blackcat7717
Did Any of you investors out their go to this fund raiser
in New Jersey Last night?
You are cordially invited to our Corporate presentation in New Jersey, to be held at the Greenbrook Country Club in North Caldwell, New Jersey on Aug. 22, 2012.
Our Company Immunovative Inc. (Symbol: IMUN) is currently developing a drug that has the potential to treat Stage IV cancer patients through an innovative approach, that includes both immunotherapy and cryoablation. Our founder,world renown immunonologist Dr. Michael Har-Noy, will be traveling from Israel to give his full presentation of his companies' groundbreaking treatments for various cancer indications. Founded in 2004, Immunovative Therapies Ltd. has progressed to Human Trials (Completed Phase I/II) and is awaiting FDA Clearance to initiate Pivotal Phase II/III trials in the near future. The Phase I/II clinical trial, completed in Carlsbad, California between September 01, 2009 - March 31, 2010, included 42 human enrollees with 11 different indications of Stage IV cancer(including: Breast, Colorectal, Pancreatic, Bladder, etc.). The results demonstrated both the benign nature of the treatment as well as strong potential indications of efficacy. The husband of a long term survivor is expected to present at the Immunovative Inc. presentation.
The Company hopes to initiate Pivotal Phase II/III trials by January 2013 or sooner. We know it's the summertime and everybody has vacation plans and lots of things to do. However this presentation is an extremely important opportunity to hear about the FUTURE of this potentially groundbreaking company. You will meet Dr. Har-Noy and listen to his comprehensive presentation about the Company's technology and current status. Finally there will be a lengthy Questions and Answer period so that all inquiries can be addressed in person.
Blackcat7717
NEWS:http://www.sys-con.com/node/2334777
Blackcat7717
Hello Million
That may not be the right decision. You would be better served to
open a starting position here and average down if you are right.
However if you are wrong you at least have your starting position.
Most of those investors that purchased @ .10 will wait to sell
at $5.00 within the next 2 years.
Blackcat7717
recommendation:
http://guerillastocktrading.com/penny-stock-newsletter-watch/?p=3265
Blackcat7717
IMUN over subscribed on Private Placement:
http://finance.yahoo.com/news/immunovative-inc-announces-oversubscription-5-110000207.html
Blackcat7717
I see IMUN between now & the next 2 months @ .50. By year end
$1.00 within 12 Month from today $2.00 or higher.
Just my opinion
Long & Strong
Blackcat7717
The underwriter was the Company and it is closed. The next
PP will be around .35 between now and the end of the year.
Blackcat7717
Wildcat Just Bought 50,000 at .04 on SCRH CHEeeeeep. Getting ready
for the NEW CLUB opening in Atlantic City soon.
Blackcat7717
Hi Badman & Wildcat
Things are very quiet on Scores, everyone waiting for the NEW Club opening.
Did you guys ever buy the stock I mention on post #529.
The company had a name Change and a directional shift.
The symbol changed from NVNC to IMUN. current price between
.25-.30 cents from .12. Looking for big things here.
Re: badman post# 529
Hi Badman
If we keep posting positive news about SCRH the stock will trade
at 1 cent. Maybe we should be posting negative news so the stock
could go up. Ha Ha Take a look at NVNC at .12 cents.
Blackcat7717
Shareholders, The O/S currently are 135,000 Million not 35 million. However the shareholders are very savvy. The company
just completed a Private Placement for 60,000 shares at $.10 for 6 million dollars.
Rumor has it that they are setting their sights on raising 50
million dollars at a higher price level. If this is so we will
be off and running. stay tuned!
Long & Strong
Blackcat7717
Last chance to buy in before the train leaves the station!
100% move from here.
Blackcat7717
Press Release
Immunovative, Inc. Announces the Retention of Winston & Strawn LLP as it’s Legal Counsel
New York, New York, July 31st, 2012 Immunovative, Inc. (“IMUN”) (OTCBB: IMUN) announced today that the company has retained the law firm of Winston & Strawn LLP as its primary outside legal counsel. Winston & Strawn is an international law firm with nearly 1,000 attorneys among 15 offices in Beijing, Charlotte, Chicago, Geneva, Hong Kong, Houston, London, Los Angeles, Moscow, New York, Newark, Paris, San Francisco, Shanghai, and Washington, D.C.
Blackcat7717
Shareholders LOOK:
Immunovative Inc. (OTCBB: IMUN) is amongst the biggest gainers on the OTC market in trading today. At last check, IMUN was trading 28.57% higher at $0.225 on volume of 2.90 million, which is well above the daily average volume of 98,571. IMUN opened at $0.17 today, and touched an intra-day high of $0.27. The stock's intra-day low of $0.17. In the last five trading sessions, IMUN has gained more than 40%, which makes the stock one the best performers on the OTC market.
Find out if IMUN can maintain its bullish approach by reading the free trend analysis report here: http://www.pennystocksvip.com/stocks/?q=IMUN
Blackcat7717
How long and what price will you sell?
Blackcat7717
New Website:
http://www.imun.com/
Blackcat7717
Management Team:
http://www.imun.com/managementteam.html
Blackcat7717